PDF(Pubmed)
Abstract：
UNASSIGNED: The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.
UNASSIGNED: PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.
UNASSIGNED: Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).
UNASSIGNED: No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.
UNASSIGNED: This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.
UNASSIGNED: PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.
UNASSIGNED: Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).
UNASSIGNED: No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.
UNASSIGNED: This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.
摘要：
■在精神分裂症谱系障碍中，大麻使用与阳性症状之间的关联是有据可查的，尤其是通过荟萃分析。然而，关于阴性症状的研究结果不一致，而其他方面，如混乱，抑郁症,和兴奋，没有被调查。此外,荟萃分析使用汇总数据丢弃重要的混杂变量，这是偏差的来源。
■PubMed,从成立到2022年9月27日，ScienceDirect和PsycINFO用于搜索出版物。我们联系了相关研究的作者，以提取原始数据集并进行个人参与者数据荟萃分析（IPDMA）。纳入标准是：通过阳性和阴性综合征量表（PANSS）评估的精神分裂症谱系障碍患者的心理病理学；大麻使用者必须诊断出大麻使用障碍或每周至少两次使用大麻。主要结果是通过3因素提取的PANSS子得分(阳性，负和一般)和5因素(正，负,杂乱无章,抑郁症,兴奋)结构。预注册可通过Prospero访问：IDCRD42022329172。
■在1149项确定的研究中，65个符合条件，21个数据集被共享，共3677例IPD和3053例完整病例。调整后的多变量分析显示，相对于不使用，大麻使用与积极维度的严重程度更高相关(3因素：调整后的平均差，aMD=0.34，95%置信区间，CI=[0.03；0.66]；5因素：aMD=0.38，95%CI=[0.08；0.63]），负维度的严重程度较低（3因素：aMD=-0.49，95％CI[-0.90；-0.09]；5因素：aMD=-0.50，95％CI=[-0.91；-0.08]），兴奋程度维度较高(aMD=0.16，95%CI=[0.03；0.28])。未发现大麻使用与混乱（aMD=-0.13，95％CI=[-0.42;0.17]）或抑郁（aMD=-0.14，95％CI=[-0.34;0.06]）之间存在关联。
■无法从当前结果中推断出因果关系。这些发现可能有利于大麻对阳性和阴性症状的有害和有益影响，分别。纵向设计需要了解大麻的作用是这种关联。报告的效应大小较小，CI较宽，对调查结果的解释应谨慎。
■这项研究没有获得任何具体的资助或资助。作者的主要财政支持由LeVinatier精神病医院提供。
■PubMed,从成立到2022年9月27日，ScienceDirect和PsycINFO用于搜索出版物。我们联系了相关研究的作者，以提取原始数据集并进行个人参与者数据荟萃分析（IPDMA）。纳入标准是：通过阳性和阴性综合征量表（PANSS）评估的精神分裂症谱系障碍患者的心理病理学；大麻使用者必须诊断出大麻使用障碍或每周至少两次使用大麻。主要结果是通过3因素提取的PANSS子得分(阳性，负和一般)和5因素(正，负,杂乱无章,抑郁症,兴奋)结构。预注册可通过Prospero访问：IDCRD42022329172。
■在1149项确定的研究中，65个符合条件，21个数据集被共享，共3677例IPD和3053例完整病例。调整后的多变量分析显示，相对于不使用，大麻使用与积极维度的严重程度更高相关(3因素：调整后的平均差，aMD=0.34，95%置信区间，CI=[0.03；0.66]；5因素：aMD=0.38，95%CI=[0.08；0.63]），负维度的严重程度较低（3因素：aMD=-0.49，95％CI[-0.90；-0.09]；5因素：aMD=-0.50，95％CI=[-0.91；-0.08]），兴奋程度维度较高(aMD=0.16，95%CI=[0.03；0.28])。未发现大麻使用与混乱（aMD=-0.13，95％CI=[-0.42;0.17]）或抑郁（aMD=-0.14，95％CI=[-0.34;0.06]）之间存在关联。
■无法从当前结果中推断出因果关系。这些发现可能有利于大麻对阳性和阴性症状的有害和有益影响，分别。纵向设计需要了解大麻的作用是这种关联。报告的效应大小较小，CI较宽，对调查结果的解释应谨慎。
■这项研究没有获得任何具体的资助或资助。作者的主要财政支持由LeVinatier精神病医院提供。
